AUS
NZ
UK
CA
USA
IND
4DMedical Limited (ASX:4DX), a global frontrunner in respiratory imaging technology, has revealed the introduction of a bipartisan bill in the US House of Representatives aimed at directing the Department of Veterans Affairs (VA) to launch a pilot program utilizing cutting-edge 4D functional lung imaging software to detect respiratory ailments and lung diseases in Veterans. Known as the AIR CARE for Vets Act (H.R.9666), the bill was co-introduced by Representatives Juan Ciscomani (Republican, Arizona) and Chris Pappas (Democrat, New Hampshire), both serving on the House Committee on Veterans' Affairs. The legislation allocates US$20 million for the pilot and specifies eligible products as FDA-authorized 4D functional lung imaging software—explicitly including 4DMedical's XV Technology® and its FDA-cleared XV LVAS® product. This marks a potentially pivotal commercial and clinical advancement for the Melbourne-based company, which already maintains an established presence in the US market.
Key Highlights
- 4DMedical Limited (ASX:4DX) is a Melbourne-headquartered global leader in respiratory imaging technology with operations in Woodland Hills, California.
- The bipartisan AIR CARE for Vets Act (H.R.9666) was introduced in the US House, directing the VA to implement a pilot program using 4D functional lung imaging software.
- The bill authorizes US$20 million for the pilot and defines eligible products as FDA-authorized 4D functional lung imaging software, a category that includes 4DMedical's XV Technology®.
- The bill has been referred to the House Committee on Veterans' Affairs and must advance through the legislative process before becoming law.
- Investors will monitor committee progress, VA engagement with 4DMedical, and updates on the company’s US commercial expansion.
Details of the AIR CARE for Vets Act (H.R.9666) and VA Directives
Introduced on 16 July 2026, the AIR CARE for Vets Act (H.R.9666) directs the Secretary of Veterans Affairs to establish a pilot program at VA facilities employing advanced 4D functional lung imaging software. The legislation further instructs the Secretary to pursue licensing agreements for eligible products defined as FDA-authorized 4D functional lung imaging software that evaluates lung function, directly encompassing 4DMedical's FDA-cleared XV LVAS® product.
The bill appropriates US$20 million to support the pilot program’s establishment and operations. While introduction signals progress, enactment is not guaranteed; the bill must be reviewed by the House Committee on Veterans' Affairs and proceed through the House legislative process. The bipartisan sponsorship by committee members underscores a favorable context for investors assessing the bill’s potential.
Bipartisan Congressional Backing and Legislative Sponsors
The AIR CARE for Vets Act was jointly introduced by Representatives Juan Ciscomani (Republican, Arizona) and Chris Pappas (Democrat, New Hampshire), both members of the House Committee on Veterans' Affairs. 4DMedical emphasizes the sustained and expanding congressional interest in 4D functional lung imaging for Veterans since 2022, rather than a one-off initiative.
Representative Ciscomani highlighted the bill’s goal to provide Veterans with access to modern technology for diagnosing service-related conditions such as lung cancer and respiratory disorders. Representative Pappas emphasized its importance for New Hampshire Veterans exposed to burn pits, which raises lung disease risks. The company update also includes support from Captain Le Roy Torres (US Army, Retired, Co-Founder of Burn Pits 360), who shared his personal experience with respiratory illness diagnosis and endorsed the legislation for improving Veterans’ access to 4D lung imaging. These statements are sourced from 4DMedical’s disclosures.
Alignment of 4DMedical's XV Technology with Eligible Product Criteria
The bill’s definition of eligible 4D functional lung imaging software as FDA-authorized to evaluate lung function directly matches 4DMedical's XV LVAS®, an FDA-cleared product within its XV Technology® platform. The company describes XV Technology® as a global leader in 4D functional lung imaging, delivered via a Software-as-a-Service (SaaS) model that supports US reimbursement pathways and a growing clinical site network.
This positions 4DMedical as a prime candidate to supply technology for the pilot program if the bill is enacted. The company asserts readiness to support such a VA pilot, though investors should recognize that enactment and program establishment depend on further government processes, including procurement and licensing.
Peer-Reviewed Clinical Research Validating XV Technology in Veterans
4DMedical references peer-reviewed multicenter studies demonstrating XV Technology®’s clinical efficacy in Veterans. Research showed the technology distinguished Veterans with biopsy-confirmed deployment-related constrictive bronchiolitis from healthy controls, even when standard diagnostic tests like spirometry were normal. This finding is clinically significant, indicating the technology’s ability to detect conditions missed by conventional VA diagnostic tools.
The update notes Veterans face elevated respiratory disease rates, often linked to service-related exposures, with many cases undetected by spirometry and conventional CT imaging. The 2022 PACT Act recognized constrictive bronchiolitis as a presumptive condition and mandated toxic-exposure screening for millions of Veterans, creating a legislative and clinical backdrop supporting the proposed advanced imaging pilot. The company has not disclosed specific screening numbers or commercial opportunity estimates related to the pilot.
Ongoing Congressional and VA Interest in 4D Lung Imaging Since 2022
The company situates the AIR CARE for Vets Act within a broader, sustained US congressional and VA focus on 4D functional lung imaging for Veterans. The 2022 Congressional appropriations committee report for Military Construction and Veterans Affairs mentioned emerging 4D lung function imaging technology and urged VA evaluation for population-wide surveillance of Veterans exposed to airborne hazards. This predates the current bill by about four years, reflecting long-term federal interest.
4DMedical views H.R.9666 as part of this ongoing policy dialogue rather than an isolated effort, indicating that legislative interest in its technology is persistent. Whether this translates into formal VA programs, licensing, or contracts will depend on legislative and governmental developments.
4DMedical’s Established US Commercial Presence and SaaS Model
4DMedical is not a pre-revenue entity seeking initial US customers. The company update highlights an established US commercial footprint, including expanding clinical sites, reimbursement pathways for functional and structural imaging, and FDA-cleared software delivered via a SaaS model. This infrastructure supports potential participation in a VA pilot without needing to build US operations from scratch.
The SaaS model licenses imaging software to clinical sites, generating recurring revenue tied to usage. Operating dual headquarters in Melbourne and Woodland Hills, California, 4DMedical targets both Australian and US markets. Specific financial details, clinical site counts, and reimbursement rates were not disclosed; investors should consult the company’s latest financial reports for detailed metrics.
CEO Andreas Fouras Comments on Legislation and Company Preparedness
4DMedical’s Managing Director, CEO, and Founder Andreas Fouras described the proposed US$20 million pilot as a landmark advancement for respiratory disease identification and management within the US Veterans healthcare system. He expressed pride in bipartisan Congressional support for expanding Veterans’ access to advanced 4D functional lung imaging, noting the disproportionate respiratory disease burden among Veterans and the limitations of current tests. Fouras commended Representatives Ciscomani and Pappas for their leadership.
He affirmed the company’s readiness to assist millions of Veterans affected by lung disease and support the pilot program envisioned by the bill. While optimistic, investors should recognize that legislative progression from bill introduction to enacted law and operational pilot involves multiple stages that may face delays or changes. The CEO’s statements indicate preparedness but do not guarantee commercial outcomes.
Risks Related to 4DMedical and Legislative Process for H.R.9666
Although H.R.9666’s introduction is a significant milestone, investors must understand it marks an early phase in a complex legislative journey. The bill’s referral to the House Committee on Veterans' Affairs initiates consideration, but many bills do not advance to a full House vote, and fewer become law within a single session. There is no assurance the AIR CARE for Vets Act will be enacted or that the VA will enter licensing agreements with 4DMedical.
Additionally, 4DMedical faces typical risks for medical technology firms at its development stage, including slower-than-expected clinical adoption, challenges to reimbursement pathways, and competition from other FDA-cleared technologies vying for VA contracts. Operating across multiple jurisdictions introduces currency and regulatory risks. The company’s update does not detail these risks; investors should review full risk disclosures in official filings before investing.
Upcoming Milestones for 4DMedical Investors to Watch
The immediate next step is the House Committee on Veterans' Affairs’ review of H.R.9666. Given both bill co-sponsors serve on this committee, it may receive favorable consideration, though outcomes remain uncertain. Investors should also track VA statements on piloting 4D functional lung imaging, further Congressional activity involving 4DMedical’s XV Technology®, and company updates on US commercial expansion.
Commercial indicators to monitor include growth in US clinical sites, reimbursement progress, and any formal VA engagements. The company has not provided financial guidance or timelines for VA-related commercial results. The announcement’s immediate impact on share price was unclear at publication; investors should observe trading and future disclosures for additional insights.
